The non-Hodgkin’s lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in targeted and precision therapies, the launch of ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.

U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences ...

Over the coming years, the Inflation Reduction Act aims to help those with Medicare save on their prescription drug costs. Learn more.

Over the coming years, the Inflation Reduction Act aims to save people with Medicare money on their prescription medications. Read more.

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology ...

I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the ...

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, ...

Calquence is also in trials for a range of B-cell malignancies and other cancers including chronic lymphocytic leukaemia (CLL), MCL, Waldenström macroglobulinaemia (WM), follicular lymphoma ...